L-carnitine Exercise Performance Randomized Trial: What the Evidence Says

Quick Answer

L-carnitine Exercise Performance Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• The results of a prior study confirmed the protective benefits of L-carnitine due to suppression of inflammation, oxidative stress, and increased autophagy (Khedr and Werida). [Werida Rehab H. (2026); evidence level 1]
• Several experimental and clinical studies have suggested that L-carnitine supplementation may confer cardiovascular benefits in CAD patients, including improved cardiac metabolism, reduced oxidative stress, attenuation of inflammatory responses, and enhanced functional outcomes (Da Silva Guimarães et al.; Dastan et al.; Lee et al.; Lee et al.; Pastoris et al.; Singhai et al.; Tarantini et al.; Xue et al.). [Werida Rehab H. (2026); evidence level 1]
• Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults. [Wang Xiaolan (2026); evidence level 3]
• By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence. [Wang Xiaolan (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For l-carnitine exercise performance randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Werida Rehab H. (2026). Therapeutic potential of L-carnitine in coronary artery disease: a systematic review. DOI: 10.1007/s10787-025-02048-7. PMCID: PMC12995981. PMID: 41709059. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12995981/
• Wang Xiaolan (2026). Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults. DOI: 10.3389/fnut.2026.1775264. PMCID: PMC13223053. PMID: 42232577. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13223053/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.